Studies in preclinical mouse tumor models show that although TIM-3 inhibitors have modest antitumor activity as monotherapy, they demonstrate considerable antitumor activity and survival when combined with PD-1/PD-L1 pathway inhibitors.7,44 INCAGN02390 is a novel, fully human Fc-engineered anti–TIM-3 immunoglobulin G1κ antibody (aglycosylated, N297A)45 (data on file, Incyte Corporation). Here, HAVCR2 is linked to neoplasm.